Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

revvity inc. - RVTY

RVTY

Close Chg Chg %
87.42 0.37 0.42%

Closed Market

87.79

+0.37 (0.42%)

Volume: 1.00M

Last Updated:

Mar 25, 2026, 4:00 PM EDT

Trade Now

Company Overview: revvity inc. - RVTY

RVTY Key Data

Open

$88.77

 Day Range

86.31 - 89.74

52 Week Range

81.36 - 118.26

 Market Cap

$9.78B

Shares Outstanding

111.80M

 Public Float

111.29M

Beta

1.10

 Rev. Per Employee

N/A

P/E Ratio

42.14

 EPS

$2.10

Yield

32.01%

 Dividend

$0.07

EX-DIVIDEND DATE

Apr 17, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

1.15M

  

RVTY Performance

1 Week
 
 2.21%
 
1 Month
 
 -10.65%
 
3 Months
 
 -9.21%
 
1 Year
 
 -16.83%
 
5 Years
 
 -32.20%
 

RVTY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 21
Full Ratings ➔

About revvity inc. - RVTY

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

RVTY At a Glance

Revvity, Inc.
77 Citypoint 4th Avenue
Waltham, Massachusetts 02451
Phone 1-781-663-6900 Revenue 2.86B
Industry Medical Specialties Net Income 242.02M
Sector Health Technology 2025 Sales Growth 3.667%
Fiscal Year-end 12 / 2026 Employees 11,000
View SEC Filings

RVTY Valuation

P/E Current 42.135
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 46.611
Price to Sales Ratio 3.95
Price to Book Ratio 1.498
Price to Cash Flow Ratio 19.43
Enterprise Value to EBITDA 16.514
Enterprise Value to Sales 4.817
Total Debt to Enterprise Value 0.247

RVTY Efficiency

Revenue/Employee 259,641.00
Income Per Employee 22,001.636
Receivables Turnover 3.835
Total Asset Turnover 0.233

RVTY Liquidity

Current Ratio 1.682
Quick Ratio 1.397
Cash Ratio 0.691

RVTY Profitability

Gross Margin 47.964
Operating Margin 14.979
Pretax Margin 9.393
Net Margin 8.474
Return on Assets 1.953
Return on Equity 3.216
Return on Total Capital 2.253
Return on Invested Capital 2.285

RVTY Capital Structure

Total Debt to Total Equity 46.869
Total Debt to Total Capital 31.912
Total Debt to Total Assets 27.926
Long-Term Debt to Equity 38.334
Long-Term Debt to Total Capital 26.101
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Revvity Inc. - RVTY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
3.31B 2.75B 2.76B 2.86B
Sales Growth
-34.64% -16.95% +0.16% +3.67%
Cost of Goods Sold (COGS) incl D&A
1.55B 1.43B 1.43B 1.49B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
427.00M 431.77M 427.85M 405.34M
Depreciation
56.40M 66.70M 68.47M 69.75M
Amortization of Intangibles
370.60M 365.07M 359.38M 335.58M
COGS Growth
-35.02% -7.91% +0.28% +3.76%
Gross Income
1.76B 1.32B 1.32B 1.37B
Gross Income Growth
-34.30% -24.91% +0.04% +3.57%
Gross Profit Margin
+53.16% +48.07% +48.01% +47.96%
2022 2023 2024 2025 5-year trend
SG&A Expense
979.61M 922.70M 912.14M 942.06M
Research & Development
221.62M 216.58M 196.84M 215.84M
Other SG&A
757.99M 706.12M 715.30M 726.22M
SGA Growth
-20.54% -5.81% -1.14% +3.28%
Other Operating Expense
- - - -
-
Unusual Expense
54.18M 132.85M 55.82M 82.63M
EBIT after Unusual Expense
726.94M 266.64M 354.70M 345.18M
Non Operating Income/Expense
28.85M 15.15M 57.70M 15.28M
Non-Operating Interest Income
3.59M 72.13M 73.19M 31.10M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
103.95M 98.81M 96.28M 92.19M
Interest Expense Growth
+1.79% -4.95% -2.57% -4.25%
Gross Interest Expense
103.95M 98.81M 96.28M 92.19M
Interest Capitalized
- - - -
-
Pretax Income
651.84M 182.98M 316.13M 268.28M
Pretax Income Growth
-49.07% -71.93% +72.77% -15.14%
Pretax Margin
+19.68% +6.65% +11.47% +9.39%
Income Tax
139.16M 3.47M 33.05M 28.39M
Income Tax - Current - Domestic
143.19M 48.98M 59.75M 22.59M
Income Tax - Current - Foreign
101.89M 78.15M 75.54M 67.29M
Income Tax - Deferred - Domestic
(61.38M) (80.46M) (45.37M) (23.13M)
Income Tax - Deferred - Foreign
(44.54M) (43.20M) (56.86M) (38.36M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
512.68M 179.50M 283.07M 239.88M
Minority Interest Expense
- - - -
-
Net Income
512.68M 179.50M 283.07M 239.88M
Net Income Growth
-45.65% -64.99% +57.70% -15.26%
Net Margin Growth
+15.48% +6.53% +10.27% +8.40%
Extraordinaries & Discontinued Operations
56.50M (297.88M) 12.76M 2.13M
Discontinued Operations
56.50M (297.88M) 12.76M 2.13M
Net Income After Extraordinaries
569.18M (118.38M) 295.83M 242.02M
Preferred Dividends
- - - -
-
Net Income Available to Common
569.18M (118.38M) 295.83M 242.02M
EPS (Basic)
4.5117 -0.9493 2.4099 2.0767
EPS (Basic) Growth
-44.44% -121.04% +353.86% -13.83%
Basic Shares Outstanding
126.16M 124.70M 122.76M 116.54M
EPS (Diluted)
4.5021 -0.9493 2.4086 2.0757
EPS (Diluted) Growth
-44.31% -121.09% +353.72% -13.82%
Diluted Shares Outstanding
126.43M 124.81M 122.82M 116.59M
EBITDA
1.21B 831.26M 838.37M 833.15M
EBITDA Growth
-33.07% -31.19% +0.86% -0.62%
EBITDA Margin
+36.48% +30.22% +30.43% +29.17%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 117.875
Number of Ratings 21 Current Quarters Estimate 1.021
FY Report Date 03 / 2026 Current Year's Estimate 5.401
Last Quarter’s Earnings 1.70 Median PE on CY Estimate N/A
Year Ago Earnings 5.06 Next Fiscal Year Estimate 5.98
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 18 18 18 18
Mean Estimate 1.02 1.30 5.40 5.98
High Estimates 1.06 1.39 5.45 6.12
Low Estimate 1.00 1.22 5.30 5.70
Coefficient of Variance 1.47 3.43 0.61 1.67

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 6 5
OVERWEIGHT 5 5 6
HOLD 10 10 9
UNDERWEIGHT 0 0 0
SELL 1 1 1
MEAN Overweight Overweight Overweight

Insider Actions for Revvity Inc. - RVTY

Date Name Shares Transaction Value
Mar 11, 2026 Anita Gonzales Please See Remarks 5,799 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2026 Anita Gonzales Please See Remarks 1,616 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 27, 2026 Miriame Victor Please See Remarks 19,984 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $95.74 per share 1,913,268.16
Feb 27, 2026 Miriame Victor Please See Remarks 18,122 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $97.13 per share 1,760,189.86
Feb 27, 2026 Miriame Victor Please See Remarks N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2026 Michelle McMurry-Heath Director 4,233 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $97.26 per share 411,701.58
Feb 20, 2026 Tajinder S. Vohra Please See Remarks 13,965 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $96.03 per share 1,341,058.95
Feb 20, 2026 Joel S. Goldberg Please See Remarks 41,514 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $96.03 per share 3,986,589.42
Feb 20, 2026 Prahlad Ramadhar Singh Please See Remarks; Director 113,312 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $96.03 per share 10,881,351.36
Feb 20, 2026 Maxwell Krakowiak Please See Remarks 17,314 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $96.03 per share 1,662,663.42
Feb 20, 2026 Maxwell Krakowiak Please See Remarks 16,412 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $96.03 per share 1,576,044.36
Feb 20, 2026 Anita Gonzales Please See Remarks 4,078 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $96.03 per share 391,610.34

Revvity Inc. in the News